Advertisement

Ophthalmologic device and pharmaceutical developer Avedro Inc. reported today that it has raised $25 million in a Series C financing round led by SCP Vitalife and Aperture Venture Partners, closing out a previously announced round.

The company said in a press release that the funds will help it expand commercial operations of the Vedera and KXL Systems outside the U.S. and to seek U.S. Food and Drug Administration clearance for the products. The Waltham company is developing systems for biomechanically strengthening and modifying the cornea.

SOURCE

Advertisement
Advertisement